Rein Therapeutics (NASDAQ:RNTX – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued on Tuesday, Marketbeat Ratings reports.
A number of other research firms have also recently issued reports on RNTX. Wall Street Zen upgraded shares of Rein Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. Weiss Ratings upgraded shares of Rein Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, August 3rd. Finally, Maxim Group began coverage on Rein Therapeutics in a research note on Monday, July 20th. They issued a “buy” rating and a $4.00 target price on the stock. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $6.00.
Get Our Latest Stock Analysis on Rein Therapeutics
Rein Therapeutics Stock Up 4.4%
Rein Therapeutics (NASDAQ:RNTX – Get Free Report) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.17. Equities research analysts anticipate that Rein Therapeutics will post -0.53 earnings per share for the current year.
Institutional Investors Weigh In On Rein Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of the stock. Susquehanna International Group LLP bought a new stake in shares of Rein Therapeutics during the 3rd quarter valued at about $35,000. HRT Financial LP bought a new position in Rein Therapeutics in the fourth quarter worth about $38,000. Chicago Partners Investment Group LLC raised its stake in Rein Therapeutics by 32.2% in the first quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company’s stock worth $53,000 after buying an additional 10,000 shares in the last quarter. Northwestern Mutual Wealth Management Co. purchased a new stake in Rein Therapeutics in the second quarter worth about $68,000. Finally, Jane Street Group LLC purchased a new stake in Rein Therapeutics in the fourth quarter worth about $72,000. 90.89% of the stock is owned by hedge funds and other institutional investors.
Rein Therapeutics Company Profile
Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.
The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.
Recommended Stories
- Five stocks we like better than Rein Therapeutics
- 3 Infrastructure Stocks Built Around the Backbone of the Economy
- Moonshot to Money: Intuitive Machines Lands $600M Defense Win
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
Receive News & Ratings for Rein Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rein Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
